6th Annual Cell Culture Technology Event Recent advances, future prospects

Filed under: News

Thursday, 07 March 2013

The Royal College of Pathologists, London, UK

Cell culture has matured to become the pivotal technology in biopharmaceutical research, development and production, and its use in this and other areas continues to expand rapidly. In vitro models are replacing animals in many tests and assays; its enormous potential in the fields of stem cell and regenerative medicine has hardly started to be realized; and its utility in research grows ever faster.

 

This conference will examine some of the latest applications of cell culture technology, some that are still “over the horizon”, and some of the problems that must be solved before it can reach its full potential.

This event has CPD accreditation

Meeting chair: Dr John Davis, Chairman of the UK Branch of the European Society for Animal Cell Technology

Event Web site: www.regonline.co.uk/cellculture2013

Talks include

Assessment of influenza pathogenicity using respiratory ex-vivo organ culture
Bethany Nash, Animal Health and Veterinary Laboratories Agency, Surrey, UK
Pathogenicity studies are historically conducted in whole body systems requiring many animals for statistical significance. We have adapted ex vivo pig organ culture methods to investigate A(H1N1)pdm09 and Eurasian lineage H5N1 influenza virus pathogenesis in both pig and ferret systems as models of host and human influenza infection. This has enabled the number of animals used to be substantially reduced. Using real-time RT-PCR and immunohistochemistry we have investigated viral infection in both upper and lower respiratory tract infections to inform influenza pandemic preparedness.

To be confirmed
To be confirmed, Sigma Aldrich, UK

Alternative cell sources for ocular surface stem cell therapy
Dr Anna O’Callaghan, UCL Institute of Ophthalmology, UK
Limbal epithelial stem cells are responsible for the maintenance and repair of the corneal surface. Injury and disease can result in a deficiency of these stem cells affecting vision in these patients. Cultured limbal epithelial stem cell therapy can be used to repair the corneal surface. It is not always possible to use the patient’s own corneal cells for this, and the use of alternative sources of stem cells from the patient such as from the mouth (oral mucosa) will be discussed.

Advances in throughput screening for cell culture
To be confirmed, Applikon Biotechnology UK

To be confirmed
Dr Nik Willoughby, Heriot-Watt University, Edinburgh

Recent advances in production of challenging proteins, using a proprietary Drosophila S2 cell-based platform: robustness, scalability, cGMP production
Dr Charlotte Dyring, CEO of Expres2ion Biotechnologies, Denmark
Drosophila S2 cells represent a efficient cGMP compatible eukaryotic platform for recombinant protein expression. Expres2ion has developed a proprietary and complete licensable production platform, to serve unmet needs in vaccine and research applications. The platform and relevant applications will be described.

Event Web site: www.regonline.co.uk/cellculture2013

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

This site is regularly updated with information regarding the one day Life Science events within the UK run by Euroscicon

Euroscicon